What is Hallux?
Hallux is a clinical-stage pharmaceutical company dedicated to revolutionizing the treatment of onychomycosis, commonly known as toenail fungus. The company's innovative approach centers on developing a novel dosage form and administration route for its flagship technology, the HTS-519 subungual Micro-Insert. This biodegradable insert is engineered to deliver high concentrations of terbinafine hydrochloride directly to the infection site, thereby maximizing effectiveness while minimizing systemic exposure for chronic onychomycosis patients. The company's focus on targeted drug delivery aims to provide a superior therapeutic option for a persistent medical condition.
How much funding has Hallux raised?
Hallux has raised a total of $16.5M across 3 funding rounds:
Series A
$7.1M
Debt
$36K
Other Financing Round
$9.4M
Series A (2015): $7.1M with participation from Deerfield Capital Management
Debt (2021): $36K led by PPP
Other Financing Round (2022): $9.4M, investors not publicly disclosed
Key Investors in Hallux
Deerfield Capital Management
Deerfield Capital Management is a prominent investment firm specializing in the healthcare sector, known for its strategic backing of companies advancing innovative medical technologies and therapies. Their involvement suggests a strong belief in Hallux's potential to address unmet needs in the treatment of onychomycosis.
PPP
Public-Private Partnership
What's next for Hallux?
With the recent major strategic investment, Hallux is poised to advance its clinical development pipeline and potentially scale its operations. This capital injection is expected to fuel further research and development, support regulatory submissions, and prepare for potential commercialization of its innovative HTS-519 Micro-Insert technology. The company's trajectory suggests a move towards broader market penetration and establishing a significant presence in the dermatological therapeutics sector.
See full Hallux company page
